224 related articles for article (PubMed ID: 28245391)
1. [Influence of Chromosome Abnormality on Therapeutic Efficacy and Prognosis of Newly Diagnosed Multiple Myeloma Treated with Bortezomib].
Sun C; Wang J; Guo HF; Zhou X; Shen YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):142-146. PubMed ID: 28245391
[TBL] [Abstract][Full Text] [Related]
2. [Retrospective Analysis of Genetics Abnormalities in Patients with Multiple Myeloma].
Wang CB; Wu J; Yang K; Su M; Zhang HY; Pan YZ; Wu T; Xi R; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1681-1687. PubMed ID: 30501704
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
5. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
6. [Clinical Efficacy and Prognosis of Double-Hit Multiple Myeloma Patients with Deletion P53 Treated with Regimen Based on Bortezomib].
Wang DM; Chen YY; Meng Z; Zhang YX; Guo SQ; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1221-1227. PubMed ID: 32798402
[TBL] [Abstract][Full Text] [Related]
7. [Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients].
Gu WW; Wang JS; Mu K; Ren G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1251-1255. PubMed ID: 32798407
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
9. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
Wang Y; Li Q; Xing S; Zhang H; Li D
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e545-e550. PubMed ID: 31262667
[TBL] [Abstract][Full Text] [Related]
10. [Detection of Molecular Cytogenetic Aberrations by Fluorescence in Situ Hybridization in Different Bone Marrow Samples of Multiple Myeloma].
Wang YF; Wang H; Xi LY; Liu Y; Dong F; Wang JJ; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1352-6. PubMed ID: 26524036
[TBL] [Abstract][Full Text] [Related]
11. [Renal Pathology and Cytogenetic Examination in Multiple Myeloma Patients with Renal Impairment--Retrospective Analysis].
Lyu J; He YX; Wang JC; Sun JP; Xie LY; He PC; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1272-1277. PubMed ID: 32798411
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of chromosomal abnormalities detected by interphase fluorescence in situ hybridization in newly diagnosed multiple myeloma patients.
Hu Y; Chen L; Sun CY; She XM; Ai LS; Qin Y
Chin Med J (Engl); 2011 Oct; 124(19):2981-5. PubMed ID: 22040539
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
[TBL] [Abstract][Full Text] [Related]
15. [Application of CD138 Immunomagnetic Sorting Myeloma Cells Combined with Fluorescence in Situ Hybridization for Detecting Cytogenetic Abnormalities of Multiple Myeloma].
Gao L; Liu Q; Shi Y; Dang H; He Q; Wang Z; Feng L; Li Y; Wang XY; Li N; Song WJ; Wang YL; Kong S; Lu J; Huang XJ; Lai YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):807-812. PubMed ID: 28641640
[TBL] [Abstract][Full Text] [Related]
16. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
17. [Influence of CD117 Expression on Response of Multiple Myeloma Patients to Chemotherapy].
Tang HL; Shu MM; Dong BX; Gu HT; Liang R; Bai QX; Yang L; Zhang T; Gao GX; Chen XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1346-51. PubMed ID: 26524035
[TBL] [Abstract][Full Text] [Related]
18. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
19. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
20. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]